These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 14666913)

  • 1. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. T-20 salvage results hold up at 48 weeks.
    Feinberg J
    AIDS Clin Care; 2003 Sep; 15(9):77-8. PubMed ID: 14666913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). T-1249 for T-20 salvage.
    Feinberg J
    AIDS Clin Care; 2003 Nov; 15(11):95-6. PubMed ID: 14682275
    [No Abstract]   [Full Text] [Related]  

  • 3. Fuzeon data review.
    GMHC Treat Issues; 2003 Mar; 17(3):6. PubMed ID: 12728857
    [No Abstract]   [Full Text] [Related]  

  • 4. [HIV-1 fusion inhibitor improves treatment in HIV-1-resistant patients].
    Blasko M
    Dtsch Med Wochenschr; 2003 May; 128(19):1032. PubMed ID: 12774800
    [No Abstract]   [Full Text] [Related]  

  • 5. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
    Goebel FD
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
    [No Abstract]   [Full Text] [Related]  

  • 6. T-20: entirely new antiretroviral.
    James JS
    AIDS Treat News; 1997 Sep; (No 279):5-6. PubMed ID: 11364691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Strategies for combating resistances in HIV therapy--an exemplifying case].
    Stoehr A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
    [No Abstract]   [Full Text] [Related]  

  • 8. Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.
    Negredo E; Bonjoch A; Paredes R; Puig J; Clotet B
    Clin Infect Dis; 2005 Sep; 41(6):901-5. PubMed ID: 16107993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HIV agents. T-20 shows long-term effectiveness and safety.
    TreatmentUpdate; 2005; 17(5):8-9. PubMed ID: 17225280
    [No Abstract]   [Full Text] [Related]  

  • 10. T-20 small program, CD4 < 50, will enroll November 27 at 3:00 P.M.
    James JS
    AIDS Treat News; 2001 Oct; (373):3. PubMed ID: 11768880
    [No Abstract]   [Full Text] [Related]  

  • 11. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
    Passaes CP; Guimarães ML; Cardoso SW; Pilotto JH; Veloso V; Grinsztejn B; Morgado MG
    J Med Virol; 2012 Dec; 84(12):1869-75. PubMed ID: 23080489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-20 continues to look promising.
    AIDS Patient Care STDS; 1999 Dec; 13(12):753. PubMed ID: 10743540
    [No Abstract]   [Full Text] [Related]  

  • 13. New-Fill on "hold" and open-label for T-20.
    Berger DS
    Posit Aware; 2002; 13(1):64-5. PubMed ID: 12216532
    [No Abstract]   [Full Text] [Related]  

  • 14. [Enfuvirtide, the first representative of a new class of drugs for the treatment of HIV infection : HIV fusion inhibitors].
    Koopmans PP
    Ned Tijdschr Geneeskd; 2003 Sep; 147(36):1726-9. PubMed ID: 14520797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enfuvirtide beneficial in experienced patients.
    AIDS Patient Care STDS; 2004 Jan; 18(1):57. PubMed ID: 15080095
    [No Abstract]   [Full Text] [Related]  

  • 16. [Fusion proteins in HIV-AIDS treatment].
    Hennemann A
    Med Monatsschr Pharm; 2003 Sep; 26(9):300-2. PubMed ID: 14526613
    [No Abstract]   [Full Text] [Related]  

  • 17. Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence for genotypic predictability of response in clinical practice.
    Gupta RK; Loveday C; Kalidindi U; Lechelt M; Skinner C; Orkin C
    Int J STD AIDS; 2007 Sep; 18(9):630-2. PubMed ID: 17785009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HIV agents. T-20 (enfurvirtide, Fuzeon).
    TreatmentUpdate; 2005; 17(1):5-6. PubMed ID: 17225316
    [No Abstract]   [Full Text] [Related]  

  • 19. T-20 being called "miraculous".
    AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412581
    [No Abstract]   [Full Text] [Related]  

  • 20. Preventing viral entry. Fusion inhibitors.
    Marks N
    Posit Living; 1999 Mar; 8(2):13. PubMed ID: 12491997
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.